A new clinical study suggests that a daily pill may significantly reduce weight regain after discontinuing injectable GLP-1 treatments such as Mounjaro and Wegovy. The drug, Orforglipron, developed by Eli Lilly, works through a mechanism similar to injectable GLP-1 therapies by mimicking a protein that suppresses appetite.
The study, published in Nature Medicine, included 376 participants in the United States who had already been receiving injectable GLP-1 treatment for more than a year and had successfully lost weight. After stopping the injections, participants were divided into two groups: one received daily orforglipron, while the other received a placebo, without knowing which treatment they were taking.
In the United States, where the pill has been approved and is already available, the lowest dose costs around $149 per month — significantly less than injectable treatments.
After one year, participants who received the pill maintained more than 70% of their previous weight loss, compared to around 38%–50% in the placebo group. At the same time, certain metabolic markers — including blood pressure, lipid levels, and glucose levels — were also maintained, potentially reducing long-term obesity-related risks such as cardiovascular disease.
However, experts note that it remains unclear how durable the results are and whether treatment can eventually be discontinued without weight regain, or whether long-term — possibly lifelong — use will be required.
Source: ΒBC
What is fyi.news?
